A nationwide study of acquired C1-inhibitor deficiency in France : Characteristics and treatment responses in 92 patients by Gobert, Delphine et al.
A nationwide study of acquired C1-inhibitor deficiency
in France : Characteristics and treatment responses in
92 patients
Delphine Gobert, Romain Paule, Denise Ponard, Pierre Levy, Ve´ronique
Fre´meaux-Bacchi, Laurence Bouillet, Isabelle Boccon-Gibod, Christian
Drouet, Ste´phane Gayet, David Launay, et al.
To cite this version:
Delphine Gobert, Romain Paule, Denise Ponard, Pierre Levy, Ve´ronique Fre´meaux-Bacchi, et
al.. A nationwide study of acquired C1-inhibitor deficiency in France : Characteristics and
treatment responses in 92 patients. Medicine, Lippincott, Williams & Wilkins, 2016, 95 (33),
pp.e4363. <10.1097/MD.0000000000004363>. <hal-01371509>
HAL Id: hal-01371509
http://hal.upmc.fr/hal-01371509
Submitted on 26 Sep 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution 4.0 International License
Observational Study Medicine®
OPENA nationwide study of acquired C1-inhibitor
deﬁciency in France
Characteristics and treatment responses in 92 patients
Delphine Gobert, MDa,
∗
, Romain Paule, MDb, Denise Ponard, PhDc,d, Pierre Levy, MDe,
Véronique Frémeaux-Bacchi, MDf, Laurence Bouillet, MD, PhDd,g,h, Isabelle Boccon-Gibod, MDd,g,h,
Christian Drouet, PhDd,i, Stéphane Gayet, MDd,j, David Launay, MD, PhDd,k,l, Ludovic Martin, MD, PhDd,m,
Arsène Mekinian, MDa, Véronique Leblond, MD, PhDb, Olivier Fain, MD, PhDa,d
Abstract
Acquired angioedema (AAE) due to C1-inhibitor (C1INH) deﬁciency is rare. Treatment options for acute attacks are variable and used
off-label. Successful treatment of the associated lymphoma with rituximab seems to prevent acute attacks in subjects with AAE. The
aim of this study was to describe AAE manifestations, its associated diseases, and patients’ responses to treatments in a
representative cohort.
A retrospective nationwide study was conducted in France. The inclusion criteria were recurrent angioedema attacks and an
acquired decrease in functional C1INH <50% of the reference value.
A total of 92 cases were included, with a median age at onset of 62 years. Facial edema and abdominal pain were the most
frequent symptoms. Fifteen patients were hospitalized in the intensive care unit because of laryngeal edema, and 1 patient died. Anti-
C1INH antibodies were present in 43 patients. The associated diseases were primarily non-Hodgkin lymphoma (n=44, with 24
splenic marginal zone lymphomas) andmonoclonal gammopathy of undetermined signiﬁcance (n=24). Three patients hadmyeloma,
1 had amyloid light-chain (of immunoglobulin) (AL) amyloidosis, 1 patient had a bronchial adenocarcinoma, and 19 patients had no
associated disease. Icatibant relieved the symptoms in all treated patients (n=26), and plasma-derived C1INH concentrate in 19 of
21 treated patients. Six patients experienced thromboembolic events under tranexamic acid prophylaxis. Rituximab prevented
angioedema in 27 of 34 patients as a monotherapy or in association with chemotherapy. Splenectomy controlled AAE in 7 patients
treated for splenic marginal zone lymphoma. After a median follow-up of 4.2 years, angioedema was on remission in 52 patients.
AAE cases are primarily associated with indolent lymphoma—especially splenic marginal zone lymphoma—and monoclonal
gammopathy of undetermined signiﬁcance but not with autoimmune diseases or other conditions. Icatibant and plasma-derived
C1INH concentrate control attacks; splenectomy and immunochemotherapy prevent angioedema in lymphoma setting.
Abbreviations: AAE= acquired angioedema, C1INH= inhibitor of C1 esterase, HAE= hereditary angioedema, IQR= interquartile
range, MGUS = monoclonal gammopathy of undetermined signiﬁcance, pdC1INH = plasma-derived C1INH concentrate, SMZL =
splenic marginal zone lymphoma, TA = tranexamic acid.
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Bradykinin-mediated angioedema manifests as recurrent edema
of the mucosa, soft tissue skin, and abdominal wall, usually
during 2 to 5 days. This condition can be life threatening when
the edema occurs in the tongue or laryngeal tract and causes
asphyxia.[1] The pathophysiological mechanisms result from the
contact phase activation that is associated with kinin production
caused by a deﬁciency in C1-inhibitor (C1INH), a serine protease
inhibitor. Kallikrein (which induces bradykinin release from its
precursor) and factor XII (which activates plasma kallikrein) are
the primary targets for C1INH. In experimental studies,
accumulation of kinins (primarily bradykinin) induces capillary
vasodilatation via the activation of endothelial B1 and B2
receptors.[2]
Bradykinin-mediated angioedema can be hereditary or
acquired. The hereditary angioedemas (HAEs) are usually caused
by autosomal dominant inheritance of SERPING1 gene
mutations. SERPING1 gene mutations result in either low
C1INH expression (type I HAE) or normal levels with reduced
C1INH function (type II HAE). HAE with normal C1INH levels
and function is less frequent and is associated with F12 gene
mutations for 25% of the affected patients.[3] Acquired
angioedema with normal C1INH levels and function is related
to the use of angiotensin-converting enzyme inhibitors.[4]
AAE that is associated with C1INH deﬁciency is rare,
approximately 10 times more rare than the hereditary forms,
which are estimated to occur in between 1/10,000 and 1/50,000
of the population.[5] The largest series describing AAE repre-
sented <50 cases.[6,7] A few clinical characteristics can help to
distinguish AAE from HAE: in AAE, the disease typically
develops after the fourth decade of life in patients with no familial
history of angioedema, and with less frequent abdominal attacks.
This condition is primarily associated with lymphoma and
monoclonal gammopathy.[6–8] Some cases are described with
cancer or autoimmune conditions [7,8]; in approximately 15% of
cases, no associated condition was identiﬁed.[7] A decrease of the
functional C1INH level <50% of the reference value is
commonly used to deﬁne the disease.[7,9] Decreased levels of
C4 and CH50 are regularly observed. C1q is also frequently
decreased in AAE but is normal in HAE. A distinction between 2
subtypes has been suggested: one is characterized by C1INH
consumption and is frequently associated with lymphoprolifer-
ative diseases, whereas the other is characterized by anti-C1INH
antibodies and is thought to have an autoimmune mechanism.[10]
However, the relevance of this distinction is questioned, as AAE
with anti-C1INH antibodies is also associated with monoclonal
gammopathy and lymphoma.[7,8]
Treatments for angioedema attacks in AAE setting are used off-
label. Plasma-derived C1INH concentrate (pdC1INH) efﬁciently
treats attacks; however, some failures have been noted and
suspected to be due to C1INH consumption.[11] Icatibant, a
competitive antagonist of the endothelial bradykinin B2 receptor,
was reported to be effective in this setting in a small study.[12] For
prevention of angioedema attacks, patients with AAE exhibit a
better response to antiﬁbrinolytics than those with HAE,[13,14]
whereas the efﬁcacy of attenuated androgens seems lower for this
indication.[7] Treatment of the underlying lymphoma with
rituximab can prevent angioedema, particularly in AAE with
anti-C1INH antibodies.[15–22]
We conducted this retrospective study to characterize AAE
manifestations, to describe its associated diseases, and to observe
the responses of angioedema to treatment.22. Patients and methods
2.1. Design and setting
We conducted a retrospective study of AAE in France. All the
procedures were performed in accordance with the principles
expressed in the Declaration of Helsinki. Our institutional review
board (Ile-de-France Committee no. 10) stated that all data
collection and processing methods fulﬁlled these requirements.
According to French legislation, no written informed consent of
patients was required.2.2. Participant inclusion and exclusion criteria
Our inclusion criteria were as follows: recurrent angioedema
attacks, deﬁned as cutaneous ormucosal edema that was resistant
to antihistaminic or corticosteroid administration, ﬁrst occurring
after 40 years; and a decrease in functional C1INH <50% of the
reference value, with decreased C1q and/or anti-C1INH anti-
bodies. Patients with hereditary forms were excluded. Data
concerning patients with asymptomatic decreases in functional
C1INH were analyzed separately.2.3. Data collection
Data collection extended from September 2013 to March 2015,
and patients were referred through the immunology laboratories
of Grenoble University Hospital and Georges Pompidou
European Hospital in Paris, which are national reference
laboratories for C1INHbiology.We then contacted the clinicians
to study the medical ﬁles.
First attack duration and attack frequency at ﬁrst medical
report were recorded. A cumulative record of different local-
izations of attacks presented over time by patients was
established. If a disease was associated, the clinical, biological,
and histological characteristics at diagnosis were recorded. AAE
and its associated diseases were considered concomitant if the
diagnosis delay was <4 months.
All samples were studied in immunology laboratory of
Grenoble University Hospital or in immunology laboratory of
Georges Pompidou European Hospital in Paris. The serum
protein concentrations of C1INH, C4, and C1q were assayed by
nephelometry (Siemens, Marburg, Germany). The complement
hemolytic activity (CH50) was determined. Plasma C1INH
function was assessed as the residual esterase activity in the
plasma samples after incubation with the C1s protease. C1INH
function was assayed as described by Drouet et al,[23] or
determined by chromogenic assay (Technochrom C1-inhibitor,
Technoclone GmbH, Vienna, Austria). To quantify the presence
of anti-C1INH autoantibodies, a slightly modiﬁed version of a
C1INH-binding enzyme-linked immunosorbent assay was
used.[24] Isotype of C1INH antibodies was determined, but light
chain component is not determined routinely.
2.4. Criteria of response to treatment
We considered the response of acute attacks of angioedema to
speciﬁc treatment—tranexamic acid (TA), icatibant, or
pdC1INH—as reported in medical ﬁles; we deﬁned response
as duration of an acute attack lasting <24 hours after
administration of treatment. For speciﬁc preventive treatments
—TA and danazol—and treatment of associated disease, we
deﬁned response as no attacks or a decrease of attack frequency
by >50% during the 6 months following administration or
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Disease status at the last available visit was assessed.
Angioedema remission was deﬁned as no attack in the previous
6months. Biological remissionwasdeﬁned as a return to normal of
C1INH function. The status of associated diseases, assessed by the
clinician in the medical ﬁle, was recorded as complete remission or
active disease—which means stability or progression.2.5. Statistical analysis
We used StatView software (SAS Institute, Inc, Cary, NC,
copyright 1992–1998). Median values were reported with the
interquartile range (IQR) and mean values were reported with
standard deviation. For group comparisons, we used Pearson x2
test or analysis of variance test, if indicated. For remission survey
assessments, we used the Kaplan–Meier and log-rank tests
(Mantel–Cox). P values <0.05 were considered statistically
signiﬁcant.3. Results
One hundred forty-four medical ﬁles were studied: 94 had been
referred by the immunology laboratory of Grenoble University
Hospital (where 540 patients with HAE are followed) and 50 by
the immunology laboratory of Georges Pompidou European
Hospital in Paris. Fifty-two patients were excluded: 1 because of
SERPING1mutation, 33 because of lack of clinical information,
and 18 patients who had asymptomatic C1INH decrease;
however, biological characteristics and associated diseases of
those asymptomatic patients were collected and are reported
further separately. We thus included 92 patients; 56 were women
(60%). The observational period extended from January 1991 to
March 2015 with 4 patients diagnosed before 2000, 26 between
2000 and 2005, 29 between 2006 and 2010, and 33 between
2011 and 2015.3.1. Characteristics of angioedema
The median age at ﬁrst manifestation was 62 years (IQR=18),
and AAE diagnoses were made after a median delay of 10months
(IQR=23).
The localizations of angioedema acute attacks are described in
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Figure 1. Cumulative record of localization of angioedema attacks over time
among patients with AAE—general cohort and subgroups according to
associated disease. A patient frequently has different localizations along time.
x2 test was applied for comparison between lymphoid malignancy, monoclonal
gammopathy, and no associated disease subgroups. AAE = acquired
angioedema.
3(75% of total cohort) and abdominal pain (60%), followed by
extremities (48%), larynx (43%), tongue (32%), and genital
organs (18%). Three patients had only abdominal attacks
without any peripheral angioedema. Fifteen patients were
admitted into the intensive care unit because of asphyxia, and
1 patient was administered an unnecessary surgery because of an
abdominal attack. Most of the patients (70%) experienced
attacks lasting 24 to 72 hours; attacks lasted >72 hours in 18%
of patients and<24 hours in 12%of patients. Thirty-nine percent
of the patients had >1 attack per month.
The median biological values at diagnosis are presented in
Table 1. C1qwas low in all but 8 patients. All of the patients were
tested for anti-C1INH antibodies, which were present in 43
patients (47%). Isotypes of anti-C1INH antibodies and associat-
ed disease are described in Table 2.
We observed signiﬁcant differences in sex, angioedema
localization, and associated conditions according to the presence
or absence of anti-C1INH antibodies (Table 3). AAE without
anti-C1INH antibodies was more frequently observed in females,
associated with lymphoid malignancy, and the C1q antigen levels
were more frequently low. AAE with anti-C1INH antibodies was
associated with more frequent attacks in the extremities, genital
organs, and larynx, and more frequently associated with
monoclonal gammopathy and idiopathic AAE. No statistical
difference in clinical characteristics of angioedema was observed
according to sex or presence of an associated disease (Fig. 1).
3.2. Associated diseases
In 73 patients, an associated disease was identiﬁed (Table 4). No
signiﬁcant differences were observed in the occurrence or types of
associated diseases according to date of diagnosis (data not
shown).
3.2.1. Lymphoid malignancy. A lymphoid malignancy was
diagnosed in 44 patients: splenic marginal zone lymphoma
(SMZL) was diagnosed in 24 patients; indolent B-cell lymphoma,
in 9 patients; small lymphocytic lymphoma/B-cell chronic
lymphocytic leukemia, in 6 patients; lymphoplasmacytic lym-
phoma, in 4 patients; and cerebral diffuse large B-cell lymphoma,
in 1 patient (Table 5). Among these 44 patients, 10 had anti-
C1INH antibodies (Table 2).
At diagnosis, the lactate dehydrogenase (LDH) value, available
for 27 patients, was within the normal range in 16 cases and was
1.5 times above the reference value in 11 cases. The mean b2-
microglobulin value was 2.29mg/L (reference value<2.50mg/L).
Serologic tests for hepatitis C virus and human immunodeﬁciency
virus were negative in all patients.
Lymphoid malignancy and angioedema diagnoses were
concomitant in 25 patients, whereas lymphoid malignancy
diagnosis preceded angioedema manifestations in 8 patients,
with a median delay of 1.1 years (IQR=2; range, 0.4–6.2), or
followed angioedema in 11 patients, after a median delay of 1
year (IQR=1.6; range, 0.4–5.0). The clinical and biological AAE
characteristics in this setting were similar to the general pattern
(Fig. 1; Table 1).
3.2.2. Monoclonal gammopathy. A monoclonal gammopathy
was associated with AAE in 28 patients, which included 24
monoclonal gammopathy of undetermined signiﬁcance (MGUS),
with a mean value of immunoglobulin 2.6g/L (standard
deviation, 1.0–13.0g/L); 3 immunoglobulin G (IgG) myeloma
cases; and 1 AL IgG amyloidosis case. Anti-C1INH antibodies
were present in 17 patients (Table 2).
Table 1
Biological characteristics of patients with acquired angioedema among general cohort and according to associated disease.
Symptomatic
patients
(n=92)
AAE associated
with lymphoid
malignancy (n=44)
AAE associated
with monoclonal
gammopathy (n=28)
AAE and no
associated
condition (n=19)
Functional C1INH, % (reference value: >70%) 21 19 22 21
C1INH antigen, mg/L (reference value: >170mg/L) 90 47 125 100
C1q antigen, % (reference value: >70% of a
pool of normal plasma)
19.5 20 17 29
C4, mg/L (reference value: >93mg/L) 15 15 15 18
CH50, % (reference value: >70% of a pool of normal plasma) 10 9 10 10
Median values are indicated. AAE = acquired angioedema, C1INH = C1-inhibitor, n = number of patients.
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concomitant in 11 patients, whereas monoclonal gammopathy
was diagnosed ﬁrst in 6 patients, with a median delay of 1.0 year
(IQR=2.1; range 0.6–8.5), or after angioedema in 11 patients,
after a median delay of 3.4 years (IQR=2.5; range 0.6–8.5). The
clinical and biological AAE characteristics in this setting were
similar to the general pattern (Fig. 1; Table 1).
3.2.3. Miscellaneous diseases. Seven patients, who displayed
lymphoma orMGUS, also had autoimmune diseases: thrombotic
antiphospholipid syndrome (n=1), cutaneous lupus (n=1),
Sjögren syndrome (n=1), immune thrombocytopenia (n=1),
Hashimoto thyroiditis (n=1), or rheumatoid arthritis (n=2).
AAE without anti-C1INH antibodies was associated with
bronchial adenocarcinoma in 1 patient.
3.2.4. No associated disease. Nineteen patients never exhib-
ited an associated condition, in spite of a median follow-up of 1.8
years (IQR=4.4). Among these 19 patients, a total body
computed tomography scan had been performed and was
normal in 15, and a bone marrow biopsy had been performed
and was normal in 4. Anti-C1INH antibodies were detected in 16
cases (Table 2). The clinical and biological AAE characteristics in
this setting were similar to the general pattern, except C1q
antigen value, higher than in the total cohort and other subgroups
(Fig. 1; Table 1).
3.3. Treatment
3.3.1. Speciﬁc treatment of angioedema. Response of
angioedema to treatment of acute attacks and preventive
treatment are detailed in Table 6.
A response to TA, which was used to treat moderate attacks,
was observed in 63% of patients. pdC1INH, at standard dose of
20UI/kg of body weight, was efﬁcient in 90% of patients; a
failure was observed in 2 patients, 1 of whom had anti-C1INH
antibodies. Icatibant consistently reduced the attack durations in
all 26 treated patients. No side effects were reported after those
treatments.
TA and danazol were effective in preventing acute attacks, with
a response occurring in 76% and 75% of the patients,
respectively. The TA treatment was complicated by venous
thromboembolic events in 6 patients. Among these patients, 3
displayed predisposing factors, which included antithrombin III
deﬁciency, antiphospholipid syndrome, and a progressive diffuse
large B-cell lymphoma. The danazol treatment was complicated
in 5 patients.
3.3.2. Associated-disease treatments and efﬁcacy on
angioedema. Rituximab was administered to 34 patients and
was indicated for lymphoma (n=10), frequent angioedema4attacks (n=14), or both (n=10). The responses of AAE to
rituximab, according to associated diseases and AAE subtypes,
are described in Fig. 2. A response was observed in 21 of 25
patients with lymphoid malignancy, in 5 of 7 patients with
MGUS, and in 1 of 2 patients with AAE with anti-C1INH
antibodies, without associated disease. Overall, a response was
observed in 27 of 34 patients (79%), including 19 of 22 (86%)
patients with AAE without anti-C1INH antibodies and 8 of 12
(67%) patients with AAE with anti-C1INH antibodies. In the
latter subgroup, 1 response to rituximab was observed among 4
subjects with IgG anti-C1INH antibodies AAE, 2 among 2 with
immunoglobulin A anti-C1INH antibodies AAE, and 5 among 6
with immunoglobulin M anti-C1INH antibodies AAE (Table 2).
Relapse of angioedema occurred in 9 cases, after a mean delay of
17 months.
Apart from the rituximab treatment, 4 lymphoproliferative
disorders were treated with chemotherapy alone, which resulted
in a response of AAE in 3 patients, and 7 patients with SMZL
were treated with a splenectomy, with a response of AAE in all
cases (Table 5). Myeloma was treated with chemotherapy in all 3
patients, and a response of AAE was observed in 2 patients; 1
patient was lost to follow-up. Cyclophosphamide and dexa-
methasone controlled the amyloidosis progression and reduced
the AAE attack frequency. Treatment for rheumatoid arthritis
with a combination of corticosteroids, hydroxychloroquine, and
methotrexate prevented angioedema attacks in 1 patient, whereas
methotrexate and then azathioprine prevented them in another
patient. Hydroxychloroquine was used in 3 other patients and
prevented angioedema attacks in 1 patient treated for a cutaneous
lupus, and in 1 patient with AAE who displayed anti-C1INH
antibodies, without any other disease.3.4. Follow-up
Patients were followed for a median duration of 4.2 years (IQR=
6.8) after AAE diagnosis. Only 7 patients were lost to follow-up.
Four patients died from the following: laryngeal angioedema
revealing AAE with anti-C1INH antibodies (n=1), lymphoma
progression (n=2), or intracerebral hemorrhage (n=1).
At the last visit, angioedema was in remission in 52 patients: 31
of them were treatment-free and 21 patients received speciﬁc
preventive treatment (TA or danazol). The associated disease,
identiﬁed in 41 of those patients, was in complete remission in 28
patients and active in 13 patients. Twenty-nine patients had an
active AAE disease at their last visit: 14 were under speciﬁc
preventive treatment, 11 received icatibant or pdC1INH for
occasional attacks, and 4 were treatment-free. The associated
disease, identiﬁed in 22 of those patients, was in complete
remission in 9 patients, and active in 13. No statistical link was
Table 2
Isotypes of anti–C1-inhibitor antibodies and monoclonal component, and response to treatment, if administered.
Patient Associated disease Anti-C1INH isotype
Monoclonal
component isotype
Response of
angioedema to treatment
3 MGUS IgM IgM Response to rituximab
11 MGUS IgM IgM k Response to rituximab
9 MGUS IgM IgM k na
14 MGUS IgM IgM l na
56 MGUS IgM IgM k na
10 MGUS IgA IgA na
26 MGUS IgA IgA na
27 MGUS IgA IgA na
50 MGUS IgA IgA l Response to rituximab
75 MGUS IgA IgA l na
22 MGUS and RA IgG IgG l na
53 MGUS IgG IgG l Response to rituximab
49 MGUS and RA IgG IgG l No response to rituximab
35 MGUS IgG IgM na
41 MGUS IgG IgM k na
69 MGUS IgG IgM l na
66 Myeloma IgG IgG k Successive response to chemother-
apy: MPT, REV DEX, REV, azacytidine
17 SMZL IgG IgG l No response to rituximab
106 SMZL IgM IgM k na
25 SMZL IgM 0 Successive response to R-cyclopho-
sphamide 6, and then R
67 Indolent B-cell lymphoma IgA IgA k Response to R-bendamustine 6
43 Indolent B-cell lymphoma IgM IgM l na
57 Indolent B-cell lymphoma IgG + IgM 0 na
64 Indolent B-cell lymphoma IgG IgM k na
72 Lymphoplasmacytic lymphoma IgM IgM Response to R-COP 6
76 Cerebral DLBCL IgM IgM k No response to R-MVBP
33 B-CLL IgM IgG k na
4 None IgM 0 Response to rituximab
12 None IgM 0 na
23 None IgM 0 na
39 None IgM 0 na
44 None IgM 0 na
52 None IgM 0 na
73 None IgM 0 na
21 None IgG 0 na
40 None IgG 0 na
55 None IgG 0 na
58 None IgG 0 na
62 None IgG 0 na
71 None IgG 0 No response to rituximab
20 None IgA 0 na
48 None IgA 0 na
59 None IgA 0 na
anti-C1INH = anti-C1INH antibody, B-CLL = B-cell chronic lymphoid leukemia, C1INH = C1-inhibitor, COP = cyclophosphamide, vincristine, prednisone, DEX = dexamethasone, DLBCL = diffuse large B-cell
lymphoma, IgA = immunoglobulin A, IgG = immunoglobulin G, IgM = immunoglobulin M, MGUS = monoclonal gammopathy of undetermined signiﬁcance, MPT = melphalan, prednisone, thalidomide, MVBP =
methotrexate, BCNU, VP16, methylprednisolone, na = not applicable, R = rituximab, RA = rheumatoid arthritis, REV = Revlimid, SMZL = splenic marginal zone lymphoma.
Gobert et al. Medicine (2016) 95:33 www.md-journal.comfound between the remission of associated conditions and AAE
outcomes (data not shown). AAE without anti-C1INH anti-
bodies was associated with a better attack-free survival than AAE
with anti-C1INH antibodies (Fig. 3).
The biological data were examined at last visit for 54 patients,
and a return to normal C1INH function was observed in only 8
patients, who all were in clinical remission. Among 46 patients
with a persistent decrease in C1INH function at last visit, 25 had
clinical remission of angioedema, including 12 treatment-free
patients. Anti-C1INH antibodies were still present in 26 patients,
12 of whom had clinical remission of angioedema.53.5. Characteristics of asymptomatic C1INH deﬁciency
Eighteen individuals with decreased C1INH function <50% of
the reference value were asymptomatic, despite a median follow-
up of 7.8 years (IQR=8.7). In those patients, the decrease in
C1INHwas revealed by complement fraction C4 consumption in
the absence of cryoglobulinemia; none of these patients displayed
anti-C1INH antibodies. The median age at ﬁrst observation was
61 years (IQR=11.5). Incidental discovery was made in the
settings of a lymphoma (n=12), MGUS (n=3), common variable
immunodeﬁciency (n=1), breast cancer (n=1), and breast cancer
associated with MGUS (n=1). Their biological patterns were
Table 3
Characteristics of acquired angioedema according to presence or
absence of anti–C1-inhibitor antibody.
AAE without
anti-C1INH
antibodies
(n=49)
AAE with
anti-C1INH
antibodies
(n=43) P value
∗
Female/male 36/13 20/23 0.008
Median age at diagnosis, y (IQR) 62 (21.8) 62 (14.6) 0.5
Median diagnosis delay, y (IQR) 0.8 (2.1) 0.8 (1.8) 0.8
Abdominal 27 (55%) 28 (65%) 0.4
Extremities 18 (37%) 26 (60%) 0.03
Larynx 17 (35%) 23 (53%) 0.008
Genital organs 4 (8%) 13 (30%) 0.008
Face 37 (75%) 32 (74%) 0.8
Tongue 16 (33%) 13 (30%) 0.8
Intensive care unit/surgery 9 (18%) 7 (16%) 0.8
Associated disease <0.001
Lymphoid malignancy 34 (69%) 9 (21%)
Monoclonal gammopathy 11 (20%) 18 (37%)
No associated condition 4 (6%) 16 (37%)
C1q antigen (low vs normal) 39 (97%) 28 (80%) 0.01
Median follow-up duration, y (IQR) 3.3 (5.2) 4.4 (4.2) 0.4
AAE = acquired angioedema, ANOVA = analysis of variance, C1INH = C1-inhibitor, IQR =
interquartile range, n = number of patients.
∗
ANOVA test for median age at diagnosis, median diagnosis delay, and median follow-up duration; x2
test for qualitative variables.
Table 4
Description of our cohort and comparison with previous series of th
Our cohort Fréme
Number of patients 92
Monoclonal gammopathy n=28; MGUS, n=24; myeloma,
n=3; AL amyloidosis, n=1
MGUS, n=
Lymphoid malignancy n=44; SMZL, n=24; SLL/B-
CLL, n=6; indolent B-cell
lymphoma, n=9;
lymphoplasmacytic lymphoma,
n=4; cerebral DLB-CL, n=1
n=2; SM
cell lym
Autoimmune disease Rheumatoid arthritis, n=2;
thrombotic APLS, n=1;
cutaneous lupus, n=1;
Sjögren syndrome, n=1; ITP,
n=1; thyroiditis, n=1
(associated with MGUS or
lymphoid malignancy in all
patients)
Relapsing
rheuma
(both a
Cancer Bronchial adenocarcinoma, n=1 Gastric ad
Others 0 Hydatidosi
No associated condition 19
AAE without anti-C1INH antibodies 49 (53%)
AAE with anti-C1INH antibodies 43 (47%)
Danazol response 23/31
TA response 34/45
pdC1INH response 19/21
Icatibant response 26/26
AAE= acquired angioedema, APLS= antiphospholipid syndrome, B-CLL= B-cell chronic lymphocytic leuke
MGUS = monoclonal gammopathy of undetermined signiﬁcance, n = number of patients, NA = nonavailab
splenic marginal zone lymphoma, TA = tranexamic acid.
Gobert et al. Medicine (2016) 95:33 Medicine
6similar to the general cohort, except for slightly higher median
C1q values: the mean value of functional C1INH was 30%; the
mean value of C1INH antigen, 95mg/L; the mean value of C1q
antigen, 28.5%; the mean value of C4, 15mg/L; and the mean
value of CH50, 9%.4. Discussion
This retrospective study describes the largest cohort of subjects
with AAE due to C1INH deﬁciency. Our observations conﬁrm
previous results from smaller studies and allow for the
description of new insights.
Although no national database for bradykinin angioedema
exists in France, we could estimate the frequency of AAE as 11%
of the 610 patients followed in Grenoble immunology laborato-
ry, which conﬁrms previous reports.[7,9] AAE occurs primarily
during the sixth decade of age, which clearly differentiates this
condition from hereditary forms.[5] Acute attacks of AAE are
primarily localized to the face and abdomen. The latter can lead
to a misdiagnosis; however, only 3 patients had isolated
abdominal attacks, which likely explains the short diagnosis
delay compared with HAE.[5,25] Half of our patients experienced
potentially life-threatening attacks because of a laryngeal or
tongue localization, 1 had unnecessary surgery for abdominal
attack, and 1 patient died of laryngeal attack, which conﬁrms the
need to diagnose and properly prevent attacks.
Our work allowed us also to identify 18 patients displaying an
asymptomatic decrease in C1INH function, which was previous-e literature of acquired angioedema with C1-inhibitor deﬁciency.
aux-Bacchi et al[8] Cicardi et al[7] Castelli et al[6]
19 23 32
11 MGUS, n=13 MGUS, n=13
ZL, n=1; indolent B-
phoma, n=1
n=5; non-Hodgkin
lymphoma, n=4;
CLL, n=1
n=9;
lymphoplasmacytic
lymphoma, n=3;
SMZL, n=2; DLBCL,
n=2; SLL, n=1;
follicular lymphoma,
n=1
chondritis, n=1;
toid arthritis, n=1
ssociated with MGUS)
0 NA
enocarcinoma, n=1 n=1 Urinary bladder cancer,
n=1; breast cancer,
n=1
s, n=1 0 0
4 4 8
0 5 (22%) 9 (28%)
19 (100%) 18 (78%) 23 (72%)
NA 2/6 NA
NA 12/13 NA
NA 9/12 NA
NA NA NA
mia, C1INH= C1-inhibitor, DLBCL= diffuse large B-cell lymphoma, ITP= immune thrombocytopenia,
le data, pdC1INH = plasma-derived C1INH concentrate, SLL = small lymphocytic lymphoma, SMZL =
T
a
b
le
5
C
lin
ic
al
,
im
m
un
o
lo
g
ic
al
,
an
d
b
io
lo
g
ic
al
ch
ar
ac
te
ri
st
ic
s
o
f
ly
m
p
ho
id
m
al
ig
na
nc
ie
s
as
so
ci
at
ed
w
it
h
ac
q
ui
re
d
an
g
io
ed
em
a.
Di
ag
no
si
s
Tu
m
or
al
si
te
s
Ci
rc
ul
at
in
g
ly
m
ph
oc
yt
es
im
m
un
op
he
no
ty
pi
ng
M
ed
ul
la
ry
ly
m
ph
oc
yt
e
im
m
un
op
he
no
ty
pi
ng
M
on
oc
lo
na
l
co
m
po
ne
nt
An
ti-
C1
IN
H
an
tib
od
ie
s
Cr
yo
gl
ob
ul
in
em
ia
/
LD
H/
b
2-
m
ic
ro
gl
ob
ul
in
Re
sp
on
se
of
an
gi
oe
de
m
a
to
tr
ea
tm
en
t
1
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
M
(3
g/
L)
0
Ty
pe
II/
1.
5N
/N
A
Re
sp
on
se
to
rit
ux
im
ab
8
SM
ZL
Ad
en
op
at
hi
es
CD
20
+
CD
5
CD
23
C
D1
0
CD
20
+
CD
5
CD
23
C
D1
0
Ig
G
k
+
Ig
M
l
(1
g/
L)
0
NA
/N
/N
A
No
tre
at
m
en
t
13
SM
ZL
Sp
le
no
m
eg
al
y
NA
CD
20
+
CD
5
CD
23
C
D1
0
0
0
NA
/N
/2
.2
5
m
g/
L
Re
sp
on
se
to
sp
le
ne
ct
om
y;
Re
sp
on
se
to
CL
B
15
SM
ZL
0
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
M
(1
g/
L)
0
Ty
pe
II/
NA
/N
A
Re
sp
on
se
to
R-
CL
B
17
SM
ZL
0
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
G
l
(3
.6
g/
L)
Ig
G
NA
/N
/N
A
No
re
sp
on
se
to
rit
ux
im
ab
18
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
NA
0
0
0/
1.
5N
/N
A
No
tre
at
m
en
t
24
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
M
l
0
NA
/N
A/
NA
Re
sp
on
se
to
R-
CL
B
25
SM
ZL
0
CD
19
+
CD
5
FM
C7
+
CD
23
±
CD
20
+
CD
5
CD
23
C
D1
0
0
Ig
M
NA
/1
.5
N/
NA
Re
sp
on
se
to
R-
cy
cl
op
ho
-
sp
ha
m
id
e,
an
d
th
en
rit
ux
i-
m
ab
29
SM
ZL
Ad
en
op
at
hi
es
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
M
l
(2
g/
L)
0
NA
/1
.5
N/
NA
Re
sp
on
se
to
rit
ux
im
ab
30
SM
ZL
Ad
en
op
at
hi
es
CD
5+
CD
19
+
CD
23

CD
5+
CD
19
+
CD
23
C
CN
1
0
0
0/
N/
NA
Re
sp
on
se
to
rit
ux
im
ab
36
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
 C
D1
0
CD
20
+
CD
5
CD
23
C
D1
0
Ig
M
(1
g/
L)
0
0/
1.
5N
/N
A
Re
sp
on
se
to
rit
ux
im
ab
38
SM
ZL
Sp
le
no
m
eg
al
y
+
ad
en
op
at
hi
es
CD
20
+
CD
79
B+
FM
C7
+
CD
23
+
CD
20
+
CD
5
CD
23
C
D1
0
Ig
M
k
(6
.9
g/
L)
0
NA
/N
/N
A
Su
cc
es
si
ve
re
sp
on
se
s
to
rit
ux
im
ab
,
CL
B
61
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
l
CD
20
+
CD
5
CD
10

Ig
M
l
(1
g/
L)
0
0/
N/
NA
Su
cc
es
si
ve
re
sp
on
se
s
to
CL
B,
R-
FC
,
au
to
lo
go
us
bo
ne
m
ar
ro
w
tra
ns
pl
an
t
63
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
NA
Ig
M
l
(4
g/
L)
0
NA
/N
/N
A
Re
sp
on
se
to
rit
ux
im
ab
68
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
No
rm
al
0
0
NA
/1
.5
N/
NA
No
tre
at
m
en
t
70
SM
ZL
Sp
le
no
m
eg
al
y
+
ad
en
op
at
hi
es
CD
20
+
CD
5
CD
10

NA
0
0
0/
NA
/N
A
Re
sp
on
se
to
rit
ux
im
ab
74
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D1
0
CD
20
+
CD
5
CD
23
C
D1
0
0
0
NA
/N
A/
NA
Su
cc
es
si
ve
re
sp
on
se
s
to
sp
le
ne
ct
om
y,
CL
B-
pr
ed
ni
-
so
ne
,
R-
FC
77
SM
ZL
Sp
le
no
m
eg
al
y
CD
79
b+
FM
C7
+
CD
5
m
on
ot
y-
pi
c
k
CD
20
+
CD
5
CD
23
C
D1
0
Ig
G
0
NA
/N
/3
.1
m
g/
L
Re
sp
on
se
to
sp
le
ne
ct
om
y
81
SM
ZL
Sp
le
no
m
eg
al
y
CD
5
CD
38
C
D1
0
CD
23
lo
w
CD
79
b
lo
w
CD
20
+
FM
C7
+
CD
20
+
CD
5
CD
23
C
D1
0
Ig
M
k
0
NA
/1
.5
N/
NA
Re
sp
on
se
to
sp
le
ne
ct
om
y;
No
re
sp
on
se
to
R-
DH
AP
83
SM
ZL
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
10

CD
20
+
CD
5
CD
23
C
D1
0
0
0
0/
1.
5N
/N
A
Re
sp
on
se
to
R-
FC
87
SM
ZL
0
CD
20
+
CD
5
CD
22
+
lo
w
CD
79
b+
+
CD
23
+
FM
C7
+
CD
43
C
D3
8
k
CD
20
+
CD
79
a+
0
0
Ty
pe
I+
ty
pe
III/
N/
N
No
tre
at
m
en
t
10
6
SM
ZL
Sp
le
no
m
eg
al
y
+
ad
en
op
at
hi
es
CD
20
+
CD
5
CD
23
C
D1
0
CD
20
+
CD
5
CD
23
C
D1
0
Ig
M
k
Ig
M
Ty
pe
III/
NA
/3
.5
m
g/
L
No
tre
at
m
en
t
10
7
SM
ZL
Sp
le
no
m
eg
al
y
CD
19
+
CD
5
m
on
ot
yp
ic
k
CD
20
+
CD
5
CD
23
C
D1
0
0
0
0/
N/
NA
Su
cc
es
si
ve
re
sp
on
se
s
to
sp
le
ne
ct
om
y,
R-
cy
cl
op
ho
-
sp
ha
m
id
e,
CL
B
10
8
SM
ZL
Sp
le
no
m
eg
al
y
+
ad
en
op
at
hi
es
CD
20
+
CD
5
CD
23
C
D1
0
NA
0
0
Ty
pe
III/
NA
/N
A
Su
cc
es
si
ve
re
sp
on
se
s
to
sp
le
ne
ct
om
y
an
d
R-
ﬂ
ud
ar
ab
in
e–
m
ito
xa
nt
ro
ne
(c
on
tin
ue
d
)
Gobert et al. Medicine (2016) 95:33 www.md-journal.com
7
T
a
b
le
5
(c
o
nt
in
ue
d
).
Di
ag
no
si
s
Tu
m
or
al
si
te
s
Ci
rc
ul
at
in
g
ly
m
ph
oc
yt
es
im
m
un
op
he
no
ty
pi
ng
M
ed
ul
la
ry
ly
m
ph
oc
yt
e
im
m
un
op
he
no
ty
pi
ng
M
on
oc
lo
na
l
co
m
po
ne
nt
An
ti-
C1
IN
H
an
tib
od
ie
s
Cr
yo
gl
ob
ul
in
em
ia
/
LD
H/
b
2-
m
ic
ro
gl
ob
ul
in
Re
sp
on
se
of
an
gi
oe
de
m
a
to
tr
ea
tm
en
t
6
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
Sp
le
no
m
eg
al
y
CD
20
+
CD
5
CD
23
C
D2
2+
NA
0
0
NA
/N
A/
NA
Re
sp
on
se
to
im
m
un
oc
he
m
-
ot
he
ra
py
(w
ith
rit
ux
im
ab
)
28
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
0
CD
20
+
CD
5
CD
23

NA
0
0
NA
/1
.5
N/
NA
Su
cc
es
si
ve
re
sp
on
se
s
to
CL
B,
R-
CV
P
37
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
Ad
en
op
at
hi
es
CD
20
+
CD
10
+
NA
Ig
M
l
(0
.1
4
g/
L)
0
NA
/1
.5
N/
N
No
tre
at
m
en
t
47
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
Sp
le
no
m
eg
al
y
+
ad
en
op
at
hi
es
CD
20
+
CD
5
CD
23
C
D2
2
+
FM
C7
+
NA
0
0
NA
/N
/N
A
Su
cc
es
si
ve
re
sp
on
se
s
to
R-
CV
P,
an
d
th
en
rit
ux
im
ab
54
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
0
CD
20
+
CD
5
CD
23
C
D2
2
+
FM
C7
+
k
NA
Ig
M
k
(1
g/
L)
0
0/
NA
/N
A
No
tre
at
m
en
t
57
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
0
CD
20
+
CD
5
CD
23
C
D2
2
+
FM
C7
+
NA
0
Ig
G
+
Ig
M
NA
/N
A/
NA
No
tre
at
m
en
t
64
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
Ad
en
op
at
hi
es
NA
CD
20
+
CD
5
CD
23
C
D2
2+
FM
C7
+
k
Ig
M
k
(5
g/
L)
Ig
G
Ty
pe
I/N
A/
NA
No
tre
at
m
en
t
67
In
do
le
nt
B-
ce
ll
lym
-
ph
om
a
Ad
en
op
at
hi
es
NA
CD
20
+
CD
5
CD
23
C
D2
2+
FM
C7
+
k
Ig
A
k
(1
g/
L)
Ig
A
NA
/N
/N
A
Re
sp
on
se
to
R-
be
nd
am
us
tin
e
5
SL
L
Sp
le
no
m
eg
al
y
CD
19
+
CD
5+
CD
23
+
CD
10
F
M
C7

CD
19
+
CD
5+
CD
23
+
CD
10
F
M
C7

0
0
NA
/1
.5
N/
NA
Re
sp
on
se
to
rit
ux
im
ab
33
B-
CL
L
0
CD
20
+
CD
5+
CD
23
+
CD
22
lo
w
FM
C7

k
lo
w
CD
20
+
CD
5+
CD
23
+
CD
22
lo
w
FM
C7
Ig
G
k
(2
.1
g/
L)
Ig
M
NA
/N
/N
A
No
tre
at
m
en
t
60
B-
CL
L
0
CD
20
+
CD
5+
CD
23
+
CD
22
lo
w
FM
C7

NA
0
0
NA
/N
A/
NA
No
re
sp
on
se
to
rit
ux
im
ab
,
an
d
th
en
CL
B
78
B-
CL
L
Sp
le
no
m
eg
al
y
CD
20
+
CD
5+
CD
23
+
CD
22
lo
w
FM
C7

No
rm
al
0
0
NA
/N
/3
.2
6
m
g/
L
No
tre
at
m
en
t
10
0
B-
CL
L
0
CD
20
+
CD
5+
CD
23
+
CD
22
lo
w
FM
C7

No
rm
al
0
0
0/
NA
/0
No
re
sp
on
se
to
CL
B,
an
d
th
en
m
in
iC
HO
P
10
9
SL
L
0
CD
19
+
CD
5+
CD
23
+
CD
10
F
M
C7

No
rm
al
0
0
NA
/N
/3
.1
m
g/
L
Re
sp
on
se
to
CL
B
an
d
pr
e-
dn
iso
ne
19
Ly
m
ph
op
la
sm
ac
yt
ic
lym
ph
om
a
0
NA
CD
20
+
CC
22
+
CD
79
a
+
CD
5
CD
10
C
D3
8
Ig
M
k
0
0/
NA
/N
A
No
tre
at
m
en
t
45
Ly
m
ph
op
la
sm
ac
yt
ic
lym
ph
om
a
Sp
le
no
m
eg
al
y
NA
CD
20
+
CD
22
+
CD
79
a
+
CD
5
CD
10
C
D1
38

Ig
M
k
(6
.4
g/
L)
0
Ty
pe
I/N
/N
A
Re
sp
on
se
to
R-
CD
72
Ly
m
ph
op
la
sm
ac
yt
ic
lym
ph
om
a
Sp
le
no
m
eg
al
y
0
CD
20
+
CD
22
+
CD
79
a
+
CD
5
CD
10
C
D1
38

Ig
M
(5
.8
g/
L)
Ig
M
NA
/N
A/
NA
Re
sp
on
se
to
R-
CV
P
10
5
Ly
m
ph
op
la
sm
ac
yt
ic
lym
ph
om
a
Sp
le
no
m
eg
al
y
NA
CD
20
+
CD
22
+
CD
79
a
+
CD
5
CD
10
C
D1
38

Ig
M
0
0/
N/
5.
4
m
g/
L
Re
sp
on
se
to
sp
le
ne
ct
om
y
76
DL
BC
L
Br
ai
n
NA
CD
20
+
CD
5-
CD
10
+
CD
79
b+
Ig
M
k
(3
.3
2
g/
L)
Ig
M
NA
/N
A/
NA
No
re
sp
on
se
to
R-
M
VB
P
B-
CL
L
=
B-
ce
llc
hr
on
ic
lym
ph
oc
yt
ic
le
uk
em
ia
,C
1I
NH
=
C1
-in
hi
bi
to
r,
CD
=
cy
cl
op
ho
sp
ha
m
id
e,
de
xa
m
et
ha
so
ne
,C
HO
P
=
cy
cl
op
ho
sp
ha
m
id
e,
do
xo
ru
bi
ci
n,
vin
cr
is
tin
e,
pr
ed
ni
so
ne
,C
LB
=
ch
lo
ra
m
bu
ci
l,
CV
P
=
cy
cl
op
ho
sp
ha
m
id
e,
vin
cr
is
tin
e,
pr
ed
ni
so
ne
,D
HA
P
=
de
xa
m
et
ha
so
ne
,c
yt
ar
ab
in
e,
ci
sp
la
tin
,D
LB
CL
=
di
ffu
se
la
rg
e
B-
ce
ll
lym
ph
om
a,
FC
=
ﬂ
ud
ar
ab
in
e,
cy
cl
op
ho
sp
ha
m
id
e,
Ig
A
=
im
m
un
og
lo
bu
lin
A,
Ig
G
=
im
m
un
og
lo
bu
lin
G,
Ig
M
=
im
m
un
og
lo
bu
lin
M
,L
DH
=
la
ct
at
e
de
hy
dr
og
en
as
e,
M
VB
P
=
m
et
ho
tre
xa
te
,B
CN
U,
VP
16
,m
et
hy
lp
re
dn
is
ol
on
e,
N
=
no
rm
al
va
lu
e,
NA
=
no
na
va
ila
bl
e
da
ta
,
R
=
rit
ux
im
ab
,
SL
L
=
sm
al
ll
ym
ph
oc
yt
ic
lym
ph
om
a,
SM
ZL
=
sp
le
ni
c
m
ar
gi
na
lz
on
e
lym
ph
om
a.
Gobert et al. Medicine (2016) 95:33 Medicine
8
[26,27]
Table 6
Response of angioedema to speciﬁc treatment.
Treatment of acute attacks Patients (n) Response Comments
Tranexamic acid 30 19 (63%) Indication: mild to moderate attacks
Icatibant 26 26 (100%) Indication: severe attacks
Plasma-derived C1INH concentrate 21 19 (90%) Indication: severe attacks
Long-term prevention of attacks Patients (n) Response Side effects
Tranexamic acid 45 34 (76%) Thromboembolic events, n=6
Danazol 31 23 (75%) Hepatitis, n=3; hypertrichosis,
n=1; erythrocytosis, n=1
C1INH = C1-inhibitor, n = number of patients. A response of treatment of acute attack was deﬁned as duration of an acute attack of <24 hours after administration of treatment. For preventive treatments, a
response was deﬁned as no attacks or a decrease of attack frequency of >50% during the 6 months following administration or the introduction of preventive treatment.
Gobert et al. Medicine (2016) 95:33 www.md-journal.comly described in 6 patients with lymphoid disease. These
cases were of asymptomatic C1INH deﬁciencies, and our
description of clinical remission of angioedema occurrences
without normalization of C1INH function raises some questions
regarding the mechanisms that induce angioedema. Activation of
the contact phase is crucial in angioedema attacks.[28] Even if
functional C1INH is very low, the activation of B1 and B2
receptors may be controlled. Angioedema severity depends on
those endothelial receptor ligands that are essentially produced
by the kinin-forming system. A recent assay was developed to
evaluate C1INH function using contact phase proteases.[29] The
hydroxychloroquine efﬁcacy in 3 of our patients, as described
previously,[30] supports the hypothesis of a high kinin-forming
capacity in clinical AAE expression.
When comparing subtypes of AAE in our cohort, signiﬁcant
clinical differences were observed. AAE without anti-C1INH
antibodies was associated with indolent lymphoid malignancy
and with lower C1q values, suggesting that C1INH consumption
occurred through C1 activation in the setting of high tumor mass
lymphoid malignancies, despite low LDH and b2-microglobulin
values. Concerning the immunological function of anti-C1INH
antibodies, hypothesis can be raised, as inhibition of the
enzymatic activity or enhancing the clearance of the molecule;
however, to date, no functional tests are available in France.AAE patients t
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Figure 2. Rituximab administration and response of AAE. A response was deﬁned
following administration or introduction of rituximab. AAE = acquired angioedema, a
gammopathy of undetermined signiﬁcance, n = number of patients, RA = rheum
9We describe a striking association of AAE with SMZL, which
was diagnosed in 24 patients in this cohort. The association of
AAE with indolent B-cell lymphoma is well known; however,
only a few cases of SMZL have been previously
reported.[6,8,15,18,31–35] A recent series describing lymphomas
associated with AAE highlights this feature.[36] SMZL is a rare
lymphoid malignancy that affects patients in their sixth decade of
age.[37] This association seems signiﬁcant because treatment for
SMZL frequently induces an AAE response.
Autoimmune diseases were reported in only 7 patients in our
cohort, and all of these patients displayed MGUS or lymphoid
malignancy; only 1 patient had cancer. Reports regarding the
association of autoimmune diseases and solid tumors with AAE
are scarce,[6,8,38,39] and might be fortuitous. Interestingly, we
describe 3 cases of AAE associated with myeloma, which is quite
rare in the literature.[40]
Among this cohort, B-cell lymphoproliferation appeared to be
the primary associated feature of AAE, with or without anti-
C1INH antibodies. However, the isotype of the monoclonal
component and of the anti-C1INH antibodies did not strictly
correlate.
Based on these results, we recommend that the diagnosis
workup of AAE should include complete blood count, circulating
lymphocyte immunophenotyping, LDH, plasmatic and urinaryreated with rituximab (n=34) 
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Figure 3. Attack-free survival among patients with acquired angioedema with
anti-C1INH antibodies and patients with acquired angioedema without anti-
C1INH antibodies. Kaplan–Meier analysis of survival without attacks among 41
patients with acquired angioedema without anti-C1INH antibodies (white circle
line) and 40 patients with acquired angioedema with anti-C1INH antibodies
(black circle line), for whom data were available; log-rank test P=0.045. C1INH
= C1-inhibitor.
Gobert et al. Medicine (2016) 95:33 Medicineprotein immunoelectrophoresis, and total body computed
tomography scan. Bone marrow aspirate or osteomedullar
biopsy should be performed in case of suspicion for lymphoma
or myeloma, and in case of frequent attacks of angioedema.
Annual screening should be repeated, especially if angioedema
attacks are not prevented by a speciﬁc treatment.
Regarding the treatment response, despite a bias due to the
retrospective nature of this study, our results allow us to
reconsider therapeutic options, and to complete the recent
consensus report.[41] The response to TA for nonsevere attacks
was moderate; in contrast, icatibant and pdC1INHs were very
effective options for severe attacks in AAE. Ecallantide is not
allowed for use in France, so we were not able to study its efﬁcacy
on AAE attacks. Prevention of attacks with antiﬁbrinolytic agents
and attenuated androgen was similar in our cohort, prompting us
to recommend providing a preventive treatment to patients but
avoiding antiﬁbrinolytics if thromboembolic risk factors are
present, since thromboembolic events occurred in 6 patients. Due
to the potential severity of attacks, patients should be prescribed
icatibant and C1INH concentrates in all cases and should be
properly educated on autoinjections.
Treatment of associated diseases, especially the treatment of
lymphoid malignancy, prevented acute attacks in most cases,
regardless of the treatment options (splenectomy, rituximab, or
immunochemotherapy). Efﬁcacy of splenectomy had been
reported in 1 case report.[34] Rituximab had already been
reported to reduce the frequency of angioedema attacks,
particularly in the presence of anti-C1INH antibodies and in
lymphoma settings.[15–22,35] In our cohort, rituximab prevented
angioedema attacks in 79% of the 34 treated patients, with a
slightly better response in patients with lymphoid malignancies
and no anti-C1INH antibodies. In patients with SMZL,
splenectomy or anti-CD20 monotherapy—especially for patients
who are reluctant to undergo surgery—is an interesting option
for angioedema prevention. A response to rituximab was also
observed in the MGUS-associated AAE, even 2 patients with
immunoglobulin A and IgG monoclonal component, which is
quite unexpected. These results support the role of B cells in the
pathophysiological mechanisms that underlie AAE; anti-C1INH
might thus be borne by a monoclonal component or be produced10by polyclonal B cells, associated with a clonal lymphoprolifera-
tion.
We recommend a regular monitoring of C1INH function,
complement parameters, and anti-C1INH antibodies under
treatment, in order to better evaluate correlation between clinical
and biological remission.5. Conclusion
This study conﬁrms the potential severity of AAE with C1INH
deﬁciency, which must be properly managed to prevent life-
threatening or disabling attacks. Considering the good response
to icatibant and pdC1INH with few side effects, these treatments
could be used in severe attacks. B-cell lymphoid malignancies
(particularly SMZL) and MGUS are strongly associated with
acquired C1INH deﬁciency. Treatment of the associated disease
controls AAE manifestations. Rituximab could be proposed;
however, we must determine the precise therapeutic scheme in
prospective studies.Acknowledgments
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